资讯
近日,浙江一位女子因在KTV唱歌时嘴唇接触话筒,感染了单纯疱疹病毒(HSV-1),引发广泛关注。 HSV-1:主要引起口唇疱疹,通过唾液、共用物品(如餐具、话筒)传播,亲吻也可能中招。 HSV-2:引发生殖器疱疹,以性接触传播为主,但部分HSV-1也可能通过口交感染生殖器。 终身潜伏性:病毒一旦感染,会藏匿于神经节中,免疫力低下时(如熬夜、压力大)便“复活”复发。 典型病程:初发时嘴唇周围出现成簇 ...
染色质可及性变化在 HSV-1 感染 4 - 6 小时开始显现:对 HSV-1 感染的 ATAC-seq 时间进程分析显示,感染 1 - 2 小时几乎未发现显著差异区域,4 小时时出现 1963 个显著区域,8 小时时增加到 7558 个。而且,早期(4 小时或更早)出现染色质可及性变化的基因表达水平 ...
为解决现有抗 HSV-2 药物疗效有限及耐药问题,研究人员开展新型螺环硫代嘧啶酮化合物抗 HSV-2 研究。结果显示,化合物 3 抗病毒活性良好,能抑制病毒吸附、复制,调节凋亡通路。这为开发新的抗 HSV-2 疗法提供了方向。 在全球范围内,病毒感染对人类健康构成了严重威胁。近年来,像 COVID-19、禽流感、寨卡病毒以及猴痘病毒等大规模病毒爆发事件频发,给人类生命和生活带来极大冲击。其中,单纯 ...
13 年
Verywell Health on MSNWhy You Should Tell Your Partner if You Have HSV-1Because the breakouts are fairly easy to manage and complications are rare, you may think that HSV-1 is not something to ...
在疫苗创新的竞技场上,绿竹生物凭借LZ901的突破性设计率先突围。作为管线中进展最快的核心产品,LZ901的核心竞争力在于其创新设计。作为全球首个基于四聚体结构设计的重组带状疱疹疫苗,LZ901通过精准抗原定位技术显著提升免疫应答效率,且同时具有高免疫原性、有效性和安全性。基于上述技术优势,绿竹生物展现出对产品竞争力的强大信心,主动发起LZ901和目前市场上唯一获批的重组带状疱疹疫苗的头对头试验, ...
3 天
Verywell Health on MSNHerpes IgG Test: Purpose and What Results MeanThis includes HSV-1, the type most commonly linked to cold sores, and HSV-2, the type mainly associated with genital herpes.
[25] PCR has shown that HSV-2, [26] and less often HSV-1, [27] causes benign recurrent lymphocytic meningitis, which is usually self-limited. HSV-2 encephalitis occurs most often in newborn babies ...
If the clinical sample contains viable virus, cytopathic effects due to the herpes virus replication occur after several days, signaling the recovery of HSV-1/2 and VZV from the sample.
Male circumcision reduces the acquisition of herpes simplex virus type 2 (HSV-2) and the prevalence of human papillomavirus (HPV) infection, reports a new study. These new data complement previous ...
It can also cause genital herpes. A majority of adults are infected with HSV-1. Type 2 ("HSV-2") spreads by sexual contact and causes herpes in the genital region of an individual. An estimated 3. ...
GSK has abandoned its clinical-stage vaccine for herpes simplex virus (HSV) after a disappointing phase 1/2 trial, ceding the ground to mRNA shots in development at Moderna and BioNTech.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果